Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Nocturnal voiding frequency does not describe nocturia-related bother.

Rose GE, Denys MA, Kumps C, Whishaw DM, Khan F, Everaert KC, Bower WF.

Neurourol Urodyn. 2019 Aug;38(6):1648-1656. doi: 10.1002/nau.24029. Epub 2019 Jun 4.

PMID:
31165518
2.

ALK positively regulates MYCN activity through repression of HBP1 expression.

Claeys S, Denecker G, Durinck K, Decaesteker B, Mus LM, Loontiens S, Vanhauwaert S, Althoff K, Wigerup C, Bexell D, Dolman E, Henrich KO, Wehrmann L, Westerhout EM, Demoulin JB, Kumps C, Van Maerken T, Laureys G, Van Neste C, De Wilde B, De Wever O, Westermann F, Versteeg R, Molenaar JJ, Påhlman S, Schulte JH, De Preter K, Speleman F.

Oncogene. 2019 Apr;38(15):2690-2705. doi: 10.1038/s41388-018-0595-3. Epub 2018 Dec 11.

PMID:
30538293
3.

Smart diapers for nursing home residents with dementia: a pilot study.

Huion A, Decalf V, Kumps C, De Witte N, Everaert K.

Acta Clin Belg. 2019 Aug;74(4):258-262. doi: 10.1080/17843286.2018.1511279. Epub 2018 Aug 27.

PMID:
30146971
4.

Prognostic and Therapeutic Implications of Circulating Androgen Receptor Gene Copy Number in Prostate Cancer Patients Using Droplet Digital Polymerase Chain Reaction.

Buelens S, Claeys T, Dhondt B, Poelaert F, Vynck M, Yigit N, Thas O, Ost P, Vandesompele J, Lumen N, Kumps C.

Clin Genitourin Cancer. 2018 Jun;16(3):197-205.e5. doi: 10.1016/j.clgc.2017.12.008. Epub 2017 Dec 29.

PMID:
29366632
5.

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

Claeys S, Denecker G, Cannoodt R, Kumps C, Durinck K, Speleman F, De Preter K.

Oncotarget. 2017 Nov 6;8(63):106820-106832. doi: 10.18632/oncotarget.22423. eCollection 2017 Dec 5.

6.

Clean Intermittent Self-Catheterization as a Treatment Modality for Urinary Retention: Perceptions of Urologists.

Weynants L, Hervé F, Decalf V, Kumps C, Pieters R, Troyer B, Everaert K.

Int Neurourol J. 2017 Sep;21(3):189-196. doi: 10.5213/inj.1734824.412. Epub 2017 Sep 12.

7.

Pathophysiology of nocturnal lower urinary tract symptoms in older patients with urinary incontinence.

Denys MA, Decalf V, Kumps C, Petrovic M, Goessaert AS, Everaert K.

Int J Urol. 2017 Nov;24(11):808-815. doi: 10.1111/iju.13431. Epub 2017 Aug 16.

8.

The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.

Claeys T, Lumen N, Kumps C, Praet M, De Meerleer G, Rottey S, Ost P, Devisschere P, Villeirs G, Fonteyne V, Decaestecker K.

Urol Oncol. 2017 Apr;35(4):152.e13-152.e22. doi: 10.1016/j.urolonc.2016.10.013. Epub 2017 Jan 30.

PMID:
28153420
9.

Circadian Variation in Post Void Residual in Nursing Home Residents With Moderate Impairment in Activities of Daily Living.

Decalf V, Huion A, Denys MA, Kumps C, Petrovic M, Everaert K.

J Am Med Dir Assoc. 2017 May 1;18(5):433-437. doi: 10.1016/j.jamda.2016.11.022. Epub 2017 Jan 17.

PMID:
28108206
10.

Androgen Receptor Gene Copy Number and Protein Expression in Treatment-Naïve Prostate Cancer.

Poelaert F, Kumps C, Lumen N, Verschuere S, Libbrecht L, Praet M, Rottey S, Claeys T, Ost P, Decaestecker K, De Meerleer G, Van Praet C.

Urol Int. 2017;99(2):222-228. doi: 10.1159/000455158. Epub 2017 Jan 5.

PMID:
28052297
11.

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.

Lambertz I, Kumps C, Claeys S, Lindner S, Beckers A, Janssens E, Carter DR, Cazes A, Cheung BB, De Mariano M, De Bondt A, De Brouwer S, Delattre O, Gibbons J, Janoueix-Lerosey I, Laureys G, Liang C, Marchall GM, Porcu M, Takita J, Trujillo DC, Van Den Wyngaert I, Van Roy N, Van Goethem A, Van Maerken T, Zabrocki P, Cools J, Schulte JH, Vialard J, Speleman F, De Preter K.

Clin Cancer Res. 2015 Jul 15;21(14):3327-39. doi: 10.1158/1078-0432.CCR-14-2024. Epub 2015 Mar 24.

12.

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.

Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprüssel A, Lindner S, De Preter K, Florin A, Heukamp LC, Klein-Hitpass L, Astrahantseff K, Kumps C, Speleman F, Eggert A, Westermann F, Schramm A, Schulte JH.

Oncogene. 2015 Jun;34(26):3357-68. doi: 10.1038/onc.2014.269. Epub 2014 Sep 1.

13.

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.

Cazes A, Lopez-Delisle L, Tsarovina K, Pierre-Eugène C, De Preter K, Peuchmaur M, Nicolas A, Provost C, Louis-Brennetot C, Daveau R, Kumps C, Cascone I, Schleiermacher G, Prignon A, Speleman F, Rohrer H, Delattre O, Janoueix-Lerosey I.

Oncotarget. 2014 May 15;5(9):2688-702.

14.

The need for transparency and good practices in the qPCR literature.

Bustin SA, Benes V, Garson J, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley G, Wittwer CT, Schjerling P, Day PJ, Abreu M, Aguado B, Beaulieu JF, Beckers A, Bogaert S, Browne JA, Carrasco-Ramiro F, Ceelen L, Ciborowski K, Cornillie P, Coulon S, Cuypers A, De Brouwer S, De Ceuninck L, De Craene J, De Naeyer H, De Spiegelaere W, Deckers K, Dheedene A, Durinck K, Ferreira-Teixeira M, Fieuw A, Gallup JM, Gonzalo-Flores S, Goossens K, Heindryckx F, Herring E, Hoenicka H, Icardi L, Jaggi R, Javad F, Karampelias M, Kibenge F, Kibenge M, Kumps C, Lambertz I, Lammens T, Markey A, Messiaen P, Mets E, Morais S, Mudarra-Rubio A, Nakiwala J, Nelis H, Olsvik PA, Pérez-Novo C, Plusquin M, Remans T, Rihani A, Rodrigues-Santos P, Rondou P, Sanders R, Schmidt-Bleek K, Skovgaard K, Smeets K, Tabera L, Toegel S, Van Acker T, Van den Broeck W, Van der Meulen J, Van Gele M, Van Peer G, Van Poucke M, Van Roy N, Vergult S, Wauman J, Tshuikina-Wiklander M, Willems E, Zaccara S, Zeka F, Vandesompele J.

Nat Methods. 2013 Nov;10(11):1063-7. doi: 10.1038/nmeth.2697.

PMID:
24173381
15.

Effective Alu repeat based RT-Qpcr normalization in cancer cell perturbation experiments.

Rihani A, Van Maerken T, Pattyn F, Van Peer G, Beckers A, De Brouwer S, Kumps C, Mets E, Van der Meulen J, Rondou P, Leonelli C, Mestdagh P, Speleman F, Vandesompele J.

PLoS One. 2013 Aug 14;8(8):e71776. doi: 10.1371/journal.pone.0071776. eCollection 2013.

16.

Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.

Kumps C, Fieuw A, Mestdagh P, Menten B, Lefever S, Pattyn F, De Brouwer S, Sante T, Schulte JH, Schramm A, Van Roy N, Van Maerken T, Noguera R, Combaret V, Devalck C, Westermann F, Laureys G, Eggert A, Vandesompele J, De Preter K, Speleman F.

PLoS One. 2013;8(1):e52321. doi: 10.1371/journal.pone.0052321. Epub 2013 Jan 4.

17.

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B, Odersky A, Peifer M, Lindner S, Spruessel A, Pattyn F, Mestdagh P, Menten B, Kuhfittig-Kulle S, Künkele A, König K, Meder L, Chatterjee S, Ullrich RT, Schulte S, Vandesompele J, Speleman F, Büttner R, Eggert A, Schulte JH.

Sci Transl Med. 2012 Jul 4;4(141):141ra91. doi: 10.1126/scitranslmed.3003967.

18.

Identification of tumoral glial precursor cells in neuroblastoma.

Acosta S, Mayol G, Rodríguez E, Lavarino C, de Preter K, Kumps C, Garcia I, de Torres C, Mora J.

Cancer Lett. 2011 Dec 15;312(1):73-81. doi: 10.1016/j.canlet.2011.08.004. Epub 2011 Aug 17.

PMID:
21903323
19.

Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.

Fieuw A, Kumps C, Schramm A, Pattyn F, Menten B, Antonacci F, Sudmant P, Schulte JH, Van Roy N, Vergult S, Buckley PG, De Paepe A, Noguera R, Versteeg R, Stallings R, Eggert A, Vandesompele J, De Preter K, Speleman F.

Int J Cancer. 2012 Jun 1;130(11):2599-606. doi: 10.1002/ijc.26317. Epub 2011 Aug 29.

20.

Isolation of disseminated neuroblastoma cells from bone marrow aspirates for pretreatment risk assessment by array comparative genomic hybridization.

Vandewoestyne M, Kumps C, Swerts K, Menten B, Lammens T, Philippé J, De Preter K, Laureys G, Van Roy N, Speleman F, Deforce D.

Int J Cancer. 2012 Mar 1;130(5):1098-108. doi: 10.1002/ijc.26133. Epub 2011 Jun 9.

21.

MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival.

Afanasyeva EA, Mestdagh P, Kumps C, Vandesompele J, Ehemann V, Theissen J, Fischer M, Zapatka M, Brors B, Savelyeva L, Sagulenko V, Speleman F, Schwab M, Westermann F.

Cell Death Differ. 2011 Jun;18(6):974-84. doi: 10.1038/cdd.2010.164. Epub 2011 Jan 14.

22.

The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors.

Castelletti D, Fiaschetti G, Di Dato V, Ziegler U, Kumps C, De Preter K, Zollo M, Speleman F, Shalaby T, De Martino D, Berg T, Eggert A, Arcaro A, Grotzer MA.

Mol Cancer Ther. 2010 Dec;9(12):3145-57. doi: 10.1158/1535-7163.MCT-10-0539. Epub 2010 Oct 1.

23.

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.

De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F.

Clin Cancer Res. 2010 Sep 1;16(17):4353-62. doi: 10.1158/1078-0432.CCR-09-2660. Epub 2010 Aug 18.

24.

Multiplex Amplicon Quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma.

Kumps C, Van Roy N, Heyrman L, Goossens D, Del-Favero J, Noguera R, Vandesompele J, Speleman F, De Preter K.

BMC Genomics. 2010 May 12;11:298. doi: 10.1186/1471-2164-11-298.

25.

An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours.

Mestdagh P, Fredlund E, Pattyn F, Rihani A, Van Maerken T, Vermeulen J, Kumps C, Menten B, De Preter K, Schramm A, Schulte J, Noguera R, Schleiermacher G, Janoueix-Lerosey I, Laureys G, Powel R, Nittner D, Marine JC, Ringnér M, Speleman F, Vandesompele J.

Oncogene. 2010 Jun 17;29(24):3583-92. doi: 10.1038/onc.2010.106. Epub 2010 Apr 12.

PMID:
20383195
26.

MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors.

Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, Vermeulen J, Kumps C, Schlierf S, De Preter K, Van Roy N, Noguera R, Laureys G, Schramm A, Eggert A, Westermann F, Speleman F, Vandesompele J.

Oncogene. 2010 Mar 4;29(9):1394-404. doi: 10.1038/onc.2009.429. Epub 2009 Nov 30.

PMID:
19946337
27.

Smoothing waves in array CGH tumor profiles.

van de Wiel MA, Brosens R, Eilers PH, Kumps C, Meijer GA, Menten B, Sistermans E, Speleman F, Timmerman ME, Ylstra B.

Bioinformatics. 2009 May 1;25(9):1099-104. doi: 10.1093/bioinformatics/btp132. Epub 2009 Mar 10.

PMID:
19276148
28.

Low-cost dedicated mini-arrays for high-throughput analysis of DNA copy-number alterations in neuroblastoma.

De Preter K, Menten B, De Brouwer S, Kumps C, Michels E, Van Roy N, Vandesompele J, Speleman F.

Cancer Lett. 2008 Sep 28;269(1):111-6. doi: 10.1016/j.canlet.2008.04.031. Epub 2008 Jun 13.

PMID:
18555593
29.

Copy number alterations and copy number variation in cancer: close encounters of the bad kind.

Speleman F, Kumps C, Buysse K, Poppe B, Menten B, De Preter K.

Cytogenet Genome Res. 2008;123(1-4):176-82. doi: 10.1159/000184706. Epub 2009 Mar 11. Review.

PMID:
19287153
30.

Submicroscopic anatomy of photoreceptors in the female scale insect Eupulvinaria hydrangeae (Homopteres, Coccideae).

Presburg M, Kumps Ch, De Vos L.

J Submicrosc Cytol Pathol. 2002 Jan;34(1):9-16.

PMID:
11989860
31.

Second-trimester cancer antigen 125 and Down's syndrome.

Van Blerk M, Smitz J, De Catte L, Kumps C, Van der Elst J, Van Steirteghem AC.

Prenat Diagn. 1992 Dec;12(12):1062-6.

PMID:
1287642

Supplemental Content

Support Center